Monopar Therapeutics Inc. (MNPR), Thursday announced positive early data from its ongoing open-label MNPR-101-Zr Phase 1 trial, confirming the compound's tumor-targeting ability in humans.
The study showcased that MNPR-101, a humanized monoclonal antibody, targets cancers expressing the urokinase plasminogen activator receptor such as breast, colorectal, bladder, ovarian, gastric, and pancreatic cancers.
Moreover, the biotechnology company has received a clearance in Australia to commence an MNPR-101-Lu Phase 1 therapeutic clinical trial, which is set to launch in the fourth quarter.
Currently, Monopar's stock is surging 65.38 percent, to $3.98 over the previous close of $2.40 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.